ASCCP 2019 Annual Scientific Meeting on Anogenital and HPV-Related Diseases
The ASCCP 2019 Annual Scientific Meeting will focus on new directions surrounding the most up-to-date advances in the prevention, screening, diagnosis and management of anogenital and HPV-related diseases. Delivered through a variety of formats, this meeting will consist of sessions focusing on topics such as screening guidelines, colposcopy standards, vulvovaginal and anal disorders, special and underserved populations, HPV vaccines and more. Through an array of educational offerings, the ASCCP 2019 Annual Scientific Meeting will bring together novice clinicians and experienced professionals who are interested in staying on the cutting edge of research dedicated to improving clinical outcomes and to reducing the burden of anogenital and HPV-related diseases around the world.
- Integrate into practice new insights from the latest research on prevention, diagnosis and management of anogenital and HPV-related diseases.
- Successfully apply consensus guidelines for cervical cancer screening and management of cervical abnormalities to women in both the general population and in special circumstances using evidence derived from epidemiological, natural history and observational studies.
- Successfully apply management strategies to women with anogenital and HPV-related diseases in special populations, especially the underserved and underscreened (transgender, incarcerated, etc.).
- Apply colposcopy to the diagnosis and management of anogenital and HPV-related diseases in ways that reflect its usefulness and maximum benefits while minimizing potential harms.
- Diagnose and treat anogenital and HPV-related diseases such as cervical, vaginal, vulvar, and anal intraepithelial neoplasia, genital warts, and other vulvar and vaginal diseases.
- Discuss strategies for prevention, screening, early detection and management of HPV-associated oropharyngeal disorders.
- Describe the biology, epidemiology, natural history, and immune response to HPV, as well as the societal costs associated with genital HPV infections.
- Identify and vaccinate patients most likely to benefit from HPV vaccines, reflecting an understanding of the efficacy, benefits, risks, and cost-effectiveness of the vaccines.
- Apply HPV testing and relevant diagnostic tests to clinical practice in a directed, evidence-based, cost-effective manner.
- Manage positive cytology and HPV test results, high risk HPV genotype results, and histologically confirmed anogenital neoplasia, reflecting current and future patient risk of high grade neoplasia.
Continuing Medical Education (CME)
ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credit(s)TM
ASCCP designates this live activity for a maximum of 18.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All those who have an opportunity to control content (Faculty, Program Directors, Reviewers, Staff, etc), are required to complete a COI based on the following instructions:
ASCCP members and the general public place great trust in the work of the Society. Real or perceived undisclosed conflicts of interest may jeopardize that trust and ASCCP’s effectiveness. Conflicts of interest also may affect the objectivity of decisions that ASCCP officers and volunteers make. To minimize the potential impact of possible conflicts of interest, the Board of Directors has determined that all participants in ASCCP activities must report all real or potential conflicts prior to the activity being developed and delivered to the learners. All disclosure forms are reviewed by the Course Director of each activity. Course Director disclosure forms are reviewed by ASCCP’s Education Committee. Most conflicts involve financial relationships with commercial interests. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. These may include pharmaceutical companies, device manufacturers or distributors, service companies, or other for-profit entities. Relationships with commercial interests may affect how officers or volunteers view products or services. They may also prompt outsiders to assume bias even when none exists, harming the reputation and effectiveness of the Society. Specific relationships with potential to create conflict of interest can include direct employment, management positions including directors and officers, royalties, consultants or board or advisory board positions, lecture fees paid by an entity (including membership on speakers bureaus or review panels), expert testimony especially to regulatory bodies or in litigation, ownership or beneficial ownership of stock or stock options, research funding, honoraria, gifts including travel or other in-kind payments (e.g., accommodations, sports tickets, appliances, electronic devices, etc.), intellectual property rights received or pending, and participation in sponsored research as a principal investigator. Contracted research funded by a commercial source also creates a potential conflict of interest; this includes research funding by which an employing institution receives a grant and manages funds and the CME provider serves as principal or named investigator on the grant. Investments made through diversified mutual funds or blind trusts in which the participant does not exercise decisional control are excluded. Usually primary employment by a nonprofit or governmental organization does not create potential for conflict, but compensation to employers based on an individual’s work with a for-profit company may create bias that must be reported. Income from commercial entities unrelated to health care does not create a potential for conflict of interest. By disclosing all relationships, participants and the Society allow others to judge the extent to which conflicts may have affected judgments in conscious or unconscious ways. If the potential for any relationship to create conflict of interest appears doubtful, then it should be disclosed.
This conference is supported by unrestricted educational grants from BD Diagnostics, Hologic, and Merck.